Beximco Pharmaceuticals Reports Strong Profits and Dividend

Beximco Pharmaceuticals Limited Sponsored GDR RegS (GB:BXP) has released an update.

Beximco Pharmaceuticals Limited has announced a substantial increase in its financial performance, with net profit after tax rising to Tk. 5,866,771,470 for the year ended June 2024, compared to Tk. 4,524,468,490 the previous year. The company also declared a 40% cash dividend and proposed a name change to Beximco Pharmaceuticals PLC, pending shareholder approval at the upcoming AGM. These developments highlight Beximco’s robust growth trajectory and commitment to shareholder value.

For further insights into GB:BXP stock, check out TipRanks’ Stock Analysis page.